Heatwurx (NASDAQ:PCSA) Posts Earnings Results, Misses Expectations By $60.58 EPS

Heatwurx (NASDAQ:PCSA) issued its quarterly earnings results on Friday. The company reported ($61.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($60.58), FiscalAI reports.

Heatwurx Price Performance

Shares of PCSA traded up $0.02 during midday trading on Friday, reaching $1.86. The stock had a trading volume of 18,724 shares, compared to its average volume of 121,503. Heatwurx has a 52 week low of $1.04 and a 52 week high of $8.88. The firm’s 50 day moving average price is $1.81 and its 200-day moving average price is $2.30. The company has a market capitalization of $5.21 million, a P/E ratio of -0.44 and a beta of 1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.